Alzamend Historical Income Statement
| ALZN Stock | USD 1.31 0.01 0.77% |
Historical analysis of Alzamend Neuro income statement accounts such as Interest Income of 0.0, Depreciation And Amortization of 48.2 K or Selling General Administrative of 4.7 M can show how well Alzamend Neuro performed in making a profits. Evaluating Alzamend Neuro income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Alzamend Neuro's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Alzamend Neuro latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alzamend Neuro is a good buy for the upcoming year.
Alzamend |
About Alzamend Income Statement Analysis
Alzamend Neuro Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Alzamend Neuro shareholders. The income statement also shows Alzamend investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Alzamend Neuro Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Alzamend Neuro. It is also known as Alzamend Neuro overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Alzamend Neuro's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Alzamend Neuro current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.At this time, Alzamend Neuro's Selling General Administrative is very stable compared to the past year. As of the 23rd of November 2024, Reconciled Depreciation is likely to grow to about 53.3 K, while Interest Expense is likely to drop 9,596.
Alzamend Neuro income statement Correlations
Click cells to compare fundamentals
Alzamend Neuro Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Alzamend Neuro income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 13.9K | 158.8K | 46.5K | 7.7K | 10.1K | 9.6K | |
| Net Income Applicable To Common Shares | (4.4M) | (5.0M) | (12.4M) | (14.9M) | (13.4M) | (12.7M) | |
| Ebit | (4.4M) | (9.9M) | (12.3M) | (14.9M) | (9.9M) | (10.4M) | |
| Net Interest Income | 13.9K | (157.1K) | (46.5K) | (7.7K) | (10.1K) | (10.6K) | |
| Depreciation And Amortization | 4.4K | 5.0M | 3.5K | 23.1K | 50.7K | 48.2K | |
| Selling General Administrative | 3.4M | 3.6M | 7.1M | 6.7M | 3.5M | 4.7M | |
| Other Operating Expenses | 4.4M | 5.0M | 12.3M | 14.9M | 9.9M | 9.4M | |
| Operating Income | (4.4M) | (5.0M) | (12.3M) | (14.9M) | (9.9M) | (10.4M) | |
| Net Income From Continuing Ops | (4.4M) | (5.0M) | (12.4M) | (14.9M) | (9.9M) | (10.4M) | |
| Research Development | 1.1M | 1.3M | 5.2M | 7.4M | 6.5M | 4.6M | |
| Ebitda | (4.4M) | (5.0M) | (12.3M) | (14.8M) | (9.9M) | (10.4M) | |
| Total Operating Expenses | 4.4M | 5.0M | 12.3M | 14.9M | 9.9M | 9.4M | |
| Income Before Tax | (4.4M) | (5.0M) | (12.4M) | (14.9M) | (9.9M) | (10.4M) | |
| Total Other Income Expense Net | 13.9K | (94.7K) | (42.5K) | (7.7K) | (10.1K) | (9.6K) | |
| Net Income | (4.4M) | (5.2M) | (12.4M) | (14.9M) | (9.9M) | (10.4M) | |
| Income Tax Expense | (13.9K) | 157.1K | 42.5K | (144.8K) | (166.6K) | (158.2K) |
Pair Trading with Alzamend Neuro
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alzamend Neuro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alzamend Neuro will appreciate offsetting losses from the drop in the long position's value.Moving together with Alzamend Stock
Moving against Alzamend Stock
| 0.47 | KZR | Kezar Life Sciences | PairCorr |
| 0.42 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.39 | NXGLW | NexGel Warrant | PairCorr |
| 0.35 | RNXT | RenovoRx | PairCorr |
The ability to find closely correlated positions to Alzamend Neuro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alzamend Neuro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alzamend Neuro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alzamend Neuro to buy it.
The correlation of Alzamend Neuro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alzamend Neuro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alzamend Neuro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alzamend Neuro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.